87 related articles for article (PubMed ID: 24196026)
1. Pharmacological modulation of farnesyltransferase subtype I attenuates mecamylamine-precipitated nicotine withdrawal syndrome in mice.
Singh TG; Rehni AK; Arora SK
Behav Pharmacol; 2013 Dec; 24(8):668-77. PubMed ID: 24196026
[TBL] [Abstract][Full Text] [Related]
2. SU-6656, a selective Src kinase inhibitor, attenuates mecamylamine-precipitated nicotine withdrawal syndrome in mice.
Rehni AK; Singh TG; Arora S
Nicotine Tob Res; 2012 Apr; 14(4):407-14. PubMed ID: 22102627
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological modulation of geranylgeranyltransferase and farnesyltransferase attenuates opioid withdrawal in vivo and in vitro.
Rehni AK; Singh TG
Neuropharmacology; 2013 Aug; 71():19-26. PubMed ID: 23415632
[TBL] [Abstract][Full Text] [Related]
4. Ro 32-0432 attenuates mecamylamine-precipitated nicotine withdrawal syndrome in mice.
Singh TG; Rehni AK; Arora S
Naunyn Schmiedebergs Arch Pharmacol; 2013 Mar; 386(3):197-204. PubMed ID: 23274455
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological modulation of the α7 nicotinic acetylcholine receptor in a mouse model of mecamylamine-precipitated nicotine withdrawal.
Jackson A; Papke RL; Damaj MI
Psychopharmacology (Berl); 2018 Jul; 235(7):1897-1905. PubMed ID: 29549391
[TBL] [Abstract][Full Text] [Related]
6. Ability of baclofen to prevent somatic manifestations and neurochemical changes during nicotine withdrawal.
Varani AP; Moutinho LM; Calvo M; Balerio GN
Drug Alcohol Depend; 2011 Dec; 119(1-2):e5-12. PubMed ID: 21733642
[TBL] [Abstract][Full Text] [Related]
7. Blockade of the expression of mecamylamine-precipitated nicotine withdrawal by calcium channel antagonists.
Biala G; Weglinska B
Pharmacol Res; 2005 May; 51(5):483-8. PubMed ID: 15749464
[TBL] [Abstract][Full Text] [Related]
8. Selective c-fos induction and decreased dopamine release in the central nucleus of amygdala in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome.
Panagis G; Hildebrand BE; Svensson TH; Nomikos GG
Synapse; 2000 Jan; 35(1):15-25. PubMed ID: 10579804
[TBL] [Abstract][Full Text] [Related]
9. Repeated administration of nicotine attenuates the development of morphine tolerance and dependence in mice.
Haghparast A; Khani A; Naderi N; Alizadeh AM; Motamedi F
Pharmacol Biochem Behav; 2008 Feb; 88(4):385-92. PubMed ID: 17915302
[TBL] [Abstract][Full Text] [Related]
10. Effects of nitric oxide synthase inhibitors in attenuating nicotine withdrawal in rats.
Jain R; Mukherjee K; Mohan D
Pharmacol Biochem Behav; 2008 Feb; 88(4):473-80. PubMed ID: 18031800
[TBL] [Abstract][Full Text] [Related]
11. Open field habituation learning is improved by nicotine and attenuated by mecamylamine administered posttrial into the nucleus accumbens.
Schildein S; Huston JP; Schwarting RK
Neurobiol Learn Mem; 2002 May; 77(3):277-90. PubMed ID: 11991758
[TBL] [Abstract][Full Text] [Related]
12. Characterization of spontaneous and precipitated nicotine withdrawal in the mouse.
Damaj MI; Kao W; Martin BR
J Pharmacol Exp Ther; 2003 Nov; 307(2):526-34. PubMed ID: 12970387
[TBL] [Abstract][Full Text] [Related]
13. Monoamine oxidase inhibition dramatically prolongs the duration of nicotine withdrawal-induced place aversion.
Guillem K; Vouillac C; Koob GF; Cador M; Stinus L
Biol Psychiatry; 2008 Jan; 63(2):158-63. PubMed ID: 17643399
[TBL] [Abstract][Full Text] [Related]
14. Nicotine abstinence in the mouse.
Isola R; Vogelsberg V; Wemlinger TA; Neff NH; Hadjiconstantinou M
Brain Res; 1999 Dec; 850(1-2):189-96. PubMed ID: 10629764
[TBL] [Abstract][Full Text] [Related]
15. Baclofen prevented the changes in c-Fos and brain-derived neutrophic factor expressions during mecamylamine-precipitated nicotine withdrawal in mice.
Varani AP; Moutinho Machado L; Balerio GN
Synapse; 2014 Nov; 68(11):508-17. PubMed ID: 25042794
[TBL] [Abstract][Full Text] [Related]
16. Lack of GABAB receptors modifies behavioural and biochemical alterations induced by precipitated nicotine withdrawal.
Varani AP; Pedrón VT; Machado LM; Antonelli MC; Bettler B; Balerio GN
Neuropharmacology; 2015 Mar; 90():90-101. PubMed ID: 25479464
[TBL] [Abstract][Full Text] [Related]
17. Acute behavioural responses to nicotine and nicotine withdrawal syndrome are modified in GABA(B1) knockout mice.
Varani AP; Moutinho LM; Bettler B; Balerio GN
Neuropharmacology; 2012 Oct; 63(5):863-72. PubMed ID: 22727822
[TBL] [Abstract][Full Text] [Related]
18. Nuclear factor-kappa-B inhibitor modulates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.
Rehni AK; Bhateja P; Singh TG; Singh N
Behav Pharmacol; 2008 May; 19(3):265-9. PubMed ID: 18469544
[TBL] [Abstract][Full Text] [Related]
19. Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice.
Bagdas D; Muldoon PP; Zhu AZ; Tyndale RF; Damaj MI
Neuropharmacology; 2014 Oct; 85():67-72. PubMed ID: 24859605
[TBL] [Abstract][Full Text] [Related]
20. Interactions between age and the aversive effects of nicotine withdrawal under mecamylamine-precipitated and spontaneous conditions in male Wistar rats.
Shram MJ; Siu EC; Li Z; Tyndale RF; Lê AD
Psychopharmacology (Berl); 2008 Jun; 198(2):181-90. PubMed ID: 18385986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
